https://rbfhss.org.br/sbrafh/issue/feed 2024-07-11T10:24:46-03:00 RBFHSS atendimento@sbrafh.org.br Open Journal Systems <p>Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde [Brazilian Journal of Hospital Pharmacy and Health Services] is the official scientific journal of the Brazilian Society of Hospital Pharmacy and Health Services - SBRAFH since 2010. RBFHSS does not charge submission or publication fees or article processing charges. RBFHSS is international circulation peer reviewed journal, publishing articles about pharmaceutical services, clinical pharmacy, patient safety, pharmacotherapy, pharmacogenetics, integrative and complementary practices, health technology assessment, hospital pharmacotechnics, applied legislation, waste management, drug stability, and compatibility, pharmacoeconomics, pharmacoepidemiology, and pharmacovigilance.</p> https://rbfhss.org.br/sbrafh/article/view/1184 2024-06-28T12:16:48-03:00 Elaine Silva MIRANDA no@no.no Simone Pozza MAHMUD no@no.no 2024-07-15T00:00:00-03:00 Copyright (c) 2024 Authors https://rbfhss.org.br/sbrafh/article/view/1153 2024-05-08T09:41:07-03:00 Diovanna Santos DE CARVALHO diovannadecarvalho@hotmail.com Rafael Alves DE SOUZA no@no.no Andrea Cassia SFORSIN no@no.no Vanusa Barbosa PINTO no@no.no Maria Cleusa MARTINS no@no.no Cleber Esteves CHAVES no@no.no

<p>Objective: this work aims to simulate the economic impact of the introduction of rivaroxaban for venous thromboembolism (VTE) prophylaxis, when compared to the therapeutic options used in the institution (unfractionated heparin and enoxaparin), in the period from January to February 2022. Methods: In a retrospective study, we analyzed the possibility of replacing the prophylaxis used in the institution with prophylaxis with rivaroxaban based on the analysis of data from the electronic medical record system, taking into account the length of stay, the medications prescribed and compliance with the institutional protocol. Patients prescribed medication for VTE prophylaxis and indicated according to progress in the medical record were included, excluding those using non-pharmacological prophylaxis. Patients with contraindications to the use of rivaroxaban, such as pregnancy and liver impairment, were also excluded. Monte Carlo Simulation was used to calculate the cost of treatment with DOACs (Direct Oral Anticoagulants), using the medicines acquisition values during the study period, and a decision tree was constructed. Results: A total of 157 patients who were prescribed one of the heparins were evaluated. Of these patients, 98 (62.4%) could undergo prophylaxis with rivaroxaban as they had no contraindication to this treatment (price recorded in January/February 2022: R$ 0.23). This new prophylaxis would generate savings of up to 98.4% for enoxaparin 40 mg (price recorded in January/February: R$ 14.26), the item that had the highest consumption, corresponding to 71.4% of patients who could use it rivaroxaban. Conclusion: The implementation of rivaroxaban for venous thromboembolism prophylaxis replacing enoxaparin proved to be beneficial in terms of costs for the hospital, which suggests that more studies should be carried out in order to increase the robustness of results and support the incorporation of this technology in the institution.</p>

2024-07-11T00:00:00-03:00 Copyright (c) 2024 Authors